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expressing cells in the developing pancreas, it is not knownwhat factors control the level of Ngn3 expression
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Endocrine islet cell differentiation requires interactions among
multiple factors. Of particular importance for islet differentiation is
the basic–helix–loop–helix protein Neurogenin 3 (Neurog 3 or Ngn3)
(Sommer et al., 1996). Ngn3 inactivation has been reported to totally
abolish endocrine differentiation (Gradwohl et al., 2000). Ngn3
controls the expression of a cohort of genes that are important for
endocrine differentiation (Gasa et al., 2004; Petri et al., 2006),
including Arx (Collombat et al., 2003), IA1 (Gierl et al., 2006; Mellitzer
et al., 2006), Hlxb9 (Li et al., 1999), MafA (Matsuoka et al., 2004),MafB
(Artner et al., 2007), NeuroD//beta2 (NeuroD1) (Naya et al., 1997),
Nkx2.2 (Sussel et al., 1998), Nkx6.1, Nkx6.2 (Henseleit et al., 2005;
Sander et al., 2000), Pax4 (Sosa-Pineda et al., 1997), Pax6 (Sander et al.,
1997; St-Onge et al., 1997), and many others (Petri et al., 2006; White
et al., 2008). Ectopic Ngn3 expression in early embryonic endodermal
cells induces precocious endocrine differentiation (Apelqvist et al.,
1999; Grapin-Botton et al., 2001; Schwitzgebel et al., 2000), possibly
by inducing the expression of its downstream target, NeuroD1, which
itself can induce endocrine differentiationwhen ectopically expressed
(Ahnfelt-Ronne et al., 2007b; Gasa et al., 2004; Schwitzgebel et al.,.
nc.2000). The well-orchestrated activation of these factors is critical for
generation of the four major endocrine cell types, α, β, δ, and PP, that
produce glucagon, insulin, somatostatin, and pancreatic polypeptide,
respectively.
In the mouse, endocrine cells are produced through two phases
(Jensen et al., 2000a). From E9–E13.5 (referred to as wave I endocrine
differentiation or primary transition), glucagon expressing α cells
account for the majority of the differentiated endocrine cells. After
E13.5 (referred to as wave II endocrine differentiation or secondary
transition), all endocrine cell types are produced in signiﬁcant num-
bers (Johansson et al., 2007; Jorgensen et al., 2007). The wave I endo-
crine cells do not contribute signiﬁcantly to the mature endocrine cell
mass (Herrera, 2000; Jensen et al., 2000a), yet their production shares
similar molecular mechanisms with the wave II cell production. For
example, loss of Ngn3 function is reported to abolish both wave I and
wave II endocrine differentiation (Gradwohl et al., 2000), although
Pdx1 is not required for wave I α cell production at all (Jonsson et al.,
1995; Ofﬁeld et al., 1996).
The key role of Ngn3 necessitates its tight expression control for
proper endocrine differentiation. Ngn3+ (Ngn3-positive) cells are pre-
sent in all embryonic stages between E9 and E18.5 in the developing
mouse pancreas (Apelqvist et al., 1999; Jensen et al., 2000a; Jorgensen
et al., 2007; Schwitzgebel et al., 2000). Yet each pancreatic cell only
transiently expresses Ngn3 in a shorter-than-48-hour time frame (Gu
et al., 2002; Schwitzgebel et al., 2000). Thus, three distinct, yet related,
532 S. Wang et al. / Developmental Biology 317 (2008) 531–540aspects of Ngn3 expression must be tightly regulated. First, the
number of Ngn3-expressing cells must be controlled to ensure a
balance between islet cell differentiation and progenitor cell prolif-
eration (Apelqvist et al., 1999; Jensen et al., 2000b). Second, Ngn3
expression must reach a threshold level to trigger endocrine
differentiation (Wilson et al., 2003). Third, Ngn3 expression need to
be down-regulated as the endocrine differentiation program is
switched on.
It is well established that Notch-mediated signaling regulates the
number of Ngn3+ cells. In pancreatic progenitors, active Notch
signaling repress Ngn3 expression by maintaining high levels of Hes1
(Apelqvist et al., 1999; Jensen et al., 2000b). Stochastic down-
regulation of Notch signaling (Kaern et al., 2005) may then reduce
Hes1 expression level and subsequently leads to the activation of
Ngn3 in a subset of progenitor cells. Lateral inhibition of Notch signa-
ling prevents the neighboring cells from activating Ngn3 to restrict
Ngn3+ cell numbers (Bertrand et al., 2002). It is less clear how Ngn3 is
activated after cells are released fromHes1 repression (Lee et al., 2001).
Complicating this issue is theﬁnding thatNgn3binds its ownpromoter
to repress its transcription (Smith et al., 2004). While this self-
inhibitory loop can help explaining the transient nature of Ngn3
expression in speciﬁc islet progenitor cells, it will also prevent the high
levels of Ngn3 activity required for endocrine commitment (Duvillie et
al., 2006). It is therefore likely that other molecules act in concert with
Ngn3 to inhibit the negative inﬂuence Ngn3 has on its own promoter.
HNF6 directly binds the Ngn3 promoter to activate Ngn3 transcription
and inactivation of HNF6 signiﬁcantly reduces Ngn3 expression (Jac-
quemin et al., 2000). However, HNF6 alone is not sufﬁcient to induce
high levels of Ngn3 expression (Lee et al., 2001). HNF1 and HNF3 are
shown to bind theNgn3 promoter, but it is not clearwhether these two
factors activate Ngn3 expression in vivo (Lee et al., 2001). Thus, it is
likely that other transcription factor(s) are required to augment the
levels of Ngn3 protein in endocrine progenitors.
The zinc ﬁnger protein Myt1b (or Nzf2b) is a transcription factor
that could potentially activate Ngn3 expression. Myt1b is one of two
proteins produced from theMyt1 locus [Myt1a (Myt1) andMyt1b] (Gu
et al., 2004; Matsushita et al., 2002). Myt1b has seven C2HC-type zinc
ﬁngers and a putative transcriptional regulatory domain. Myt1a is
identical to Myt1b except that it is shorter in its N-terminus and has 6
zinc ﬁngers (Matsushita et al., 2002; Romm et al., 2005; Wang et al.,
2007). In all tissues examined, Myt1b is the predominantly expressed
isoform (Gu et al., 2004; Matsushita et al., 2002). Myt1 has two
paralogs, Myt1l and Myt3 (st18) (Armstrong et al., 1997; Blasie and
Berg, 2000; Kim et al., 1997; Kim and Hudson, 1992; Nielsen et al.,
2004; Romm et al., 2005; Yee and Yu, 1998). These genes are highly
expressed in developing neural tissues (Kim et al., 1997; Lein et al.,
2007; Matsushita et al., 2002), and could behave either as transcrip-
tional activators or repressors in a cell-context dependent manner
(Bellefroid et al., 1996; Romm et al., 2005). In Xenopus, xMyT1 and
xNgnR1 (an ortholog of Ngn3) synergistically promote neurogenesis
(Bellefroid et al., 1996). In the embryonic pancreas, only Myt1 is
expressed at a detectable level in both endocrine progenitors and
differentiated, hormone-producing cells (Gu et al., 2004). Loss ofMyt1
function partially impairs endocrine cell differentiation and result in
glucose intolerance in pancreas-speciﬁc Myt1 nullizygous animals
(Wang et al., 2007). FurthermoreMyt1 expressionpartially depends on
the activities of Nkx6.1 and/or Nkx6.2 gene products (Henseleit et al.,
2005; Nelson et al., 2007). These data suggest that Myt1 has a role in
endocrine cell differentiation. However, because Myt1l and Myt3
expression is activated in theMyt1−/− pancreas, possibly compensating
for loss of Myt1 function, it remains obscure how Myt1 regulates
endocrine differentiation (Wang et al., 2007). Particularly, it is not clear
whether Myt1b functions upstream or downstream of Ngn3 (Ahnfelt-
Ronne et al., 2007a; Gu et al., 2004; Wang et al., 2007) and whether
Myt1b acts as a transcription repressor or activator during isletogen-
esis (Bellefroid et al., 1996; Romm et al., 2005).Here we describe the genetic interactions betweenMyt1 and Ngn3
using both loss-of-function and gain-of-function analyses in mouse
tissues. We demonstrate that Myt1b induces precocious endocrine
differentiation in a Pdx1-independent, but Ngn3-dependent, manner.
Pancreatic Myt1 expression largely, but not totally, relies on Ngn3
activation. Signiﬁcantly, we ﬁnd that Myt1b up-regulates Ngn3
expression in pancreatic progenitors and that Ngn3 can induce Myt1
expression in both mouse cells in vivo and cell culture in vitro. Un-
expectedly, glucagon-expressing cells are constantly detected in Ngn3
deﬁcient embryonic pancreata, and most of these cells co-express
Myt1. Finally, we demonstrate that the transcriptional activation pro-
perty of Myt1 is required for endocrine differentiation, suggesting that
Myt1 functions as a transcriptional activator. These ﬁndings suggest
that Myt1 and Ngn3 form a feed-forward expression loop to promote
endocrine differentiation.Materials and methods
Mouse strains and care
Mouse production and care follow standard protocols approved by the Vanderbilt
Medical Center IACUC. For embryonic staging, the noon of vaginal plug appearance was
counted as embryonic day 0.5 (E0.5). For routine mouse embryo production, the CD1
mouse strain was utilized (Charles River Laboratories, Inc., Wilmington, MA). For
transgenic mouse production, B6/D2 mice were used (Charles River Laboratories, Inc.
Wilmington, MA). Subsequent strain maintenance and crosses utilized CD1 mice. The
Pdx1tTA mouse strain was described before (Holland et al., 2002). Genotyping follows
published methods.
DNA constructs and transgenic animal derivation
In order to ectopically express Myt1b, a minigene that contained intron # 6 of the
Myt1b transcript was constructed using PCR and conventional molecular cloning. The
ﬁnal construct includes the full Myt1b open reading frame with minimal 5′UTR and 3′
UTR. In order to use the Teto promoter to drive gene expression, we PCR-ampliﬁed the
TetO-CMV promoter from pTRE2 (Clontech, Paolo Alto, CA) and inserted in front of the
Myt1b minigene. A SV40 PolyA signal was then inserted at the 3′ end of the Myt1b
minigene to complete the construction. A similar approachwas utilized for construction
of tetO-Ngn3. Transgenic animal production followed standard pronuclear injection
method. Genotyping utilized PCR-based technique. Myt1btet mouse lines use oligos 5′-
GCGTGTACGGTGGGAGGCCTATAT-3′ and 5′-ACTCTGTAAGCTTCGATGTCTGGA-3′.
Expected fragment: 360 nt. Ngn3tet utilizes oligos 5′-GCGTGTACGGTGGGAGGCCTATAT-
3′ and 5′-GGGTGGAATTGGAACTGAGCACT-3′. Expected fragment: 300 nt.
In order to produce the Myt1b–Vp16 and Myt1b–EnR constructs, the cDNA coding
for the second and third zinc ﬁngers of Myt1b was PCR-ampliﬁed with two oligos:
5′-GATCCTTCCAGGGTGGAGAAG-3′ and 5′-GCTTCTCATGAGATTTGGCTAAT-3′. The DNA
fragment was fused in frame with cDNAs encoding Vp16 (aa400–488) or EnR (2–298)
protein (Muhr et al., 2001) to produce the desired constructs. In order to generate
the Myt1b luciferase reporter construct, the putative mouse Myt1b promoter,
including a conserved 1.8 kb element, was PCR-ampliﬁed and cloned upstream of
a luciferase reporter. The construct was transfected together with a Ngn3 expression
vector into two well-established cell lines, the 3T3 ﬁbroblast and P19 carcinoma cell
lines. The oligos used were: forward: 5′-TTGTAGCACATATTGGCTTCTCC-3′. Reverse:
5′-GCTCCAATATATCTGTTTACTC-3′. The PCR fragment was cloned into the PGL3
luciferase reporter vector (Promega, Madison, WI). The NeuroD-luciferase construct
was described previously (Huang et al., 2000). Luciferase assay followed standard
protocol (Williams et al., 1989).
Ngn3 targeting
TheNgn3 locus targeting followed a standard protocol. The targeting vector contains
the following features sequentially: 5.3 kb Ngn3 5′arm-LoxP-Ngn3 open reading frame-
FRT-pGK-neo-FRT-LoxP-CreERT-1.3 kb Ngn3 3′arm. The 5′arm and 3′armwere obtained
from 129svev genomic DNA using long range PCR. The Primers utilized: 5′arm forward:
5/-GGGTGTTATATGTGTGCCAAGGGCT-3′, 5′arm reverse: 5/-CTGCGGTTGGGAAAAAATG-
GAAGGTGT-3′. 3′ arm forward: 5′-GAAGCTCCGCGCCCGACGCGGAGGGC-3′, 3′ arm
reverse: 5′-CTTGTGAAGATTCTCGACGTTCATC-3′. The DNA vector, containing a FRT-
ﬂanked pGK-neo selection cassette and DTA for selection, is previously described (Wang
et al., 2007). DNA electroporation utilized TL1 ES cells (Wang et al., 2007). ES cell
selection and blastocyst injection followstandardmethods. Both Southern blot and PCR-
based assays were used to select targeted ES cells clones. Southern blot utilized a DNA
fragment ampliﬁed by oligos 5′-CTAGAATGCCTAGGAAGAGGAA-3′ and 5′-CCACAT-
CATGGCAGTGTGTCCTGA-3′ as probe. Oligos used for PCR-based genotyping: 722: 5′-
CTATCCACTGCTGCTTGTCACTG-3′. 723: 5′-TGTGTCTCTGGGGACACTTGGAT-3′. jv45: 5′-
TTCCGGTTATTCAACTTGCACC-3′. The Ngn3− allele produces a 350 bp band with (722 +
Jv45) but eliminates the wild type 219 bp band ampliﬁed with (722 +723).
Fig. 1. Derivation of mouse lines that ectopically expressMyt1b and Ngn3. (A) Pancreatic
Myt1b expression (red) at E10.5. Wild type (WT), which showed identical Myt1
expression pattern as Pdx1tTA/+ pancreas, and Pdx1tTA/tTA (labeled as tTA/tTA) pancreata
were used as controls. The presence ofMyt1btet2 (labeled asMyt1b) led toMyt1b ectopic
expression in the presence of tTA. Pdx1 (green) or glucagon staining (green) were used
tomark the position of the pancreatic buds. Note that Myt1 antibodies only stain frozen,
lightly ﬁxed sections, on which the Pdx1 signal appears diffuse. (B) Quantiﬁcation of
Myt1b ectopic expression in control and Myt1b; Pdx1tTA/+ pancreata. The number of
Myt1b+ cells is normalized against the number of Pdx1+ cells. (C) Ngn3 expression
(green) in WT and Ngn3tet8; Pdx1tTA (labeled as Ngn3; tTA) pancreata. White broken
lines, pancreatic region. Note the apparent thickening of pancreatic epithelium that
ectopically expresses Ngn3. All panels used identical scales, bar=20 μm.
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Chicken electroporation was previously described (Ahnfelt-Ronne et al., 2007a;
Grapin-Botton et al., 2001; Gu et al., 2004). Brieﬂy, fertilized White Leghorn eggs
(Triova, Denmark) were incubated at 38 °C for 55 h. Electroporation was performed on
chicken embryos at HH st. 10–15 (Hamburger and Hamilton, 1992). The DNA with a
ﬁxed concentration of 2 μg/μl in PBS (with 1 mM MgCl2, 3 mg/ml carboxymethylcellu-
lose, 0.66 mg/ml Fast Green) was injected into the blastocoels of windowed eggs. Three
to ﬁve square 50 ms pulses of 7–15 V were applied from a BTX ECM830 electroporator.
The eggs were sealed and allowed to develop for 52–72 h at 38 °C. After incubation, the
whole embryo was ﬁxed. The gut derived tissues were then collected for gene
expression analyses (Ahnfelt-Ronne et al., 2007b).
Immunohistochemistry/immunoﬂuorescence
Immunoﬂuorescence/immunohistochemistry followed established protocols. Tis-
sues were stained either as frozen sections or parafﬁn sections. Whole mount immu-
noﬂuorescence strictly followed the protocol depicted in Ahnfelt-Ronne et al. (2007b).
For frozen sections, dissected tissues were immediately frozen in OCT and sectioned
when needed. Sectioned tissues were collected onto Superfrost-plus slides, left at room
temperature for 30 min, and ﬁxed in 4% paraformaldehyde at room temperature for
15 min. Slides were washed in PBS, permealized in 0.1% triton X-100, and
immunostained. For parafﬁn section, mouse tissues were ﬁxed in 4% paraformaldehyde
overnight at 4 °C or 4 h at room temperature. They would then be prepared for section
following routine procedures. Primary antibodies used were: guinea pig anti-glucagon
(Dako, Carpinteria, CA), Rabbit anti-MafB, gifts fromR. Stein (Matsuoka et al., 2004), goat
anti-Pdx1, a gift from C. Wright, guinea pig anti-Ngn3, a gift from M. Sander (Seymour
et al., 2007), rabbit anti-Ngn3 (Gu et al., 2002), rabbit anti-Myt1 (Wang et al., 2007),
rabbit anti-Foxa2 (Santa Cruz Biotechnologies, Santa Cruz, CA), mouse anti-Nkx6.1 and
mouse anti-Pax6 (Development Hybridoma Bank, University of Iowa, Iowa, IA), rabbit
anti-PC1/3 (Chemicon, Temetula, CA). Secondary antibodies usedwere: FITC-conjugated
donkey anti-rabbit IgG; Cy3-conjugated donkey anti-rabbit IgG, Cy3-conjugated donkey
anti-mouse IgG, Cy3-conjugated donkey anti-guinea pig IgG, Cy3-conjugated donkey
anti-goat, and Cy5-conjugated donkey anti-rabbit (Jackson Immunoresearch, West
Grove, PA). All antibodies utilized a1:500–1:2000.
Microscopy and statistical analysis
All ﬂuorescent images were obtained using confocal microscopy. For quantiﬁcation
of glucagon expression and Myt1b ectopic expression, samples were frozen and
sectioned at 15 μm intervals. All sections were then collected from individual sample
and stained for hormone and transcription factor expression. Confocal optical sections
were taken at 0.4–0.6 μm intervals on all stained tissues. For Myt1b level estimation in
each cell, all optical sections for individual nucleus are projected to one picture. The
ﬂuorescence intensity within each nucleus was then compared using BIOQUANT true-
color windows system (R&M Biometrics, Nashville, TN). For quantiﬁcation of Nkx6.1 and
MafB expression, parafﬁn-sections at 6 μm intervals were utilized. In this case, only one
optical section of each tissue section was counted. Statistical analyses utilized standard
Student T test. A P-value of 0.05 or better was considered signiﬁcant. All quantiﬁcation
data are presented as the mean±standard error over the mean.
Results
Derivation of transgenic mouse lines that express Myt1b and Ngn3 in a
tTA-dependent fashion
Our previous studies of ectopic gene expression in chicken embryo-
nic endodermal cells suggest that Myt1b induces endocrine differ-
entiation (Ahnfelt-Ronne et al., 2007a; Gu et al., 2004). Yet our inability
to precisely control the timing and protein level of ectopic gene
expression in chicken embryos led to a considerable variability in
endocrine induction efﬁciency. In addition, loss of gene function is not
achievable in chicken tissues.We therefore combined studies inmouse
and chicken to determine how Myt1b interacts with Ngn3 to induce
endocrine differentiation.
We ﬁrst examined the Myt1b–Ngn3 interaction by a gain of func-
tion approach. We used the well-established, inducible TetOff/TetOn
system to regulate Myt1b and Ngn3 ectopic expression in pancreatic
cells (Gossen et al., 1994). Speciﬁcally, we derived transgenic mouse
lines that utilized a TetO-CMV synthetic promoter to control the
expression ofMyt1b or Ngn3 (Myt1btet and Ngn3tet). The expression of
Myt1b and Ngn3 in these animals could be activated by a trans-
activator, tTA, in the absence of tetracycline or doxycycline (Dox)
(Gossen et al., 1994). This approach avoided the possible lethality
caused byuncontrolled ectopicMyt1b orNgn3 expression inpancreaticcells and allowed for the derivation of stable mouse lines, in which
Myt1b or Ngn3 production could be activated by providing active tTA
in desired cell types at speciﬁc stages. We chose a knockin mouse line
that expresses tTA under the control of the Pdx1 promoter (Holland et
al., 2002) to activate Myt1b or Ngn3 ectopic expression in pancreatic
cells. We expected the compound Myt1btet; Pdx1tTA/+ and Ngn3tet;
Pdx1tTA/+ animals would ectopically expressMyt1b andNgn3 in most, if
not all, of the Pdx1+ progenitors without Dox.
SevenMyt1btet and nineNgn3tet independent transgenic mouse lines
were derived through pronuclear injection. As expected, none of these
animal lines ectopically expressed the transgene in the absence of tTA
(data not shown). One of theMyt1btet transgenic lines (Myt1btet2), when
Fig. 2. Ectopic Myt1b expression induces glucagon expression. (A) The relative number
(mean±S.E.M.) of glucagon-expressing cells in E11.5 embryos (tTA=Pdx1tTA. Myt1b=
Myt1btet2). (B–E) Myt1 and glucagon (gluc) production in representative sections of
E11.5 pancreata. Scale bars=20 μm.
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in 20.5±9.5% (n=6) of the Pdx1+ cells in the pancreas (Figs. 1A and B).
By comparison, only 7.3±0.8% (n=5) of Pdx1+ cells produced detect-
able Myt1 in the Pdx1tTA/+ control pancreas. Signiﬁcantly, pancreatic
Myt1b production in Myt1btet; Pdx1tTA/+ individuals and wild type
littermates appeared at comparable levels on per cell basis (Fig. 1A), as
judged by ﬂuorescence intensity within each nuclei during side-by-
side immunoﬂuorescence staining (see Materials and Methods). We
also examined Myt1 production in Myt1btet; Pdx1tTA/tTA pancreata, in
which no functional Pdx1 existed, yet more tTA was expected to be
produced within each cell (Holland et al., 2002).Myt1was ectopically
expressed in most, if not all, of the cells in the Myt1btet; Pdx1tTA/tTA
prospective pancreatic epithelium, suggesting that a higher Myt1b
production could be achieved by increasing the Pdx1tTA dosage (Fig.
1A). We explored whether Myt1b production could be activated at
other developmental stages by controlling the availability of Dox
during embryonic development. Plugged female animals were fed
with Dox only between E7.5 and E12.5. Myt1b production was then
characterized at E15.5 and E17.5 in Myt1btet; Pdx1tTA/+ pancreata. We
found that this manipulation could not drive ectopicMyt1b expression
in more pancreatic cells than in control littermates, other than a few
individual differentiated islet cells seemed to have a higher level of
Myt1b protein (Supplementary Fig. 1). Similarly, whenwe fed plugged
females with Dox between E7.5 and E18.5, we could not detect
signiﬁcant Myt1b over-expression in the Pdx1-expressing postnatal
cells either (data not shown). This deﬁciency prevented us from stud-
ying the effect of Myt1b ectopic expression in a temporally controlled
manner. The remaining six Myt1tet mouse lines did not show detect-
able ectopic gene expression when combined with Pdx1tTA and were
not maintained.
Seven Ngn3tet transgenic lines showed wide spread ectopic Ngn3
expression when combined with the Pdx1tTA allele in early embryonic
pancreas (Fig. 1C and data not shown). Consistent with published data
that ectopic Ngn3 expression induces precocious endocrine differ-
entiation, nearly all pancreatic cells in the Ngn3tet; Pdx1tTA/+ animals
were converted to glucagon-expressing cells after E11.5 (data not
shown). Most of the Pdx1+ cells in the Ngn3tet; Pdx1tTA/+ animals
appeared to have delaminated from the developing epithelium, con-
sistent with previous ﬁndings that Ngn3 induces epithelial-to-mesen-
chymal transition (Apelqvist et al., 1999; Grapin-Botton et al., 2001;
Schwitzgebel et al., 2000). One of these transgenic lines, Ngn3tet8,
that produced Ngn3 protein in a comparable level to that of wild
type littermates, on a per cell basis, was used for the following studies
(Fig. 1C).
Myt1b is sufﬁcient to induce endocrine differentiation in pancreatic cells
Myt1btet2; Pdx1tTA/+ animals were derived by standard genetic cros-
ses in the absence of Dox. This allowed forMyt1b ectopic expression in
pancreatic progenitors as soon as Pdx1 expressionwas turned on (Hol-
land et al., 2002). Glucagon expression was examined to determine
whether Myt1b was sufﬁcient to induce endocrine differentiation at
several stages (E10.5, E11.5, and E12.5). EctopicMyt1 expression signi-
ﬁcantly increased the number of glucagon+ cells in the developing
pancreas at E11.5 (Figs. 2A–C and data not shown). The expression of
insulin, pancreatic polypeptide, and somatostatinwas not appreciably
altered (data not shown). In order to examine whether sustained
Myt1b production at stages later than E12.5 enhances endocrine
differentiation, we examined hormone expression in Myt1btet2;
Pdx1tTA/+ and Pdx1tTA/+ control pancreata, in the absence of Dox, at
E17.5 and E18.5. At both stages, Myt1btet2; Pdx1tTA/+ pancreata did not
produce signiﬁcantly more hormone-expressing cells than control
littermate. This result is consistent with the ﬁnding that ectopicMyt1b
expression could not be activated at stages after E13.5 (Supplementary
Fig. 1), making it impossible to determine whether Myt1b is sufﬁcient
to induce endocrine differentiation at later embryonic stages.We examined glucagon production in the Myt1btet2; Pdx1tTA/tTA
animals to determine whether Myt1b induces endocrine differentia-
tion in a Pdx1-dependent pathway. E11.5 Myt1btet2; Pdx1tTA/tTA pan-
creata had 1.8 foldmore glucagon+ cells than Pdx1tTA/tTA littermates (Figs.
2A, D, and E), suggesting that Myt1b is sufﬁcient to induce endocrine
differentiation in the complete absence of Pdx1. Unlike endodermal cells
that ectopically expressed Ngn3, which largely differentiated to endo-
crine cells (Apelqvist et al., 1999; Schwitzgebel et al., 2000), only about
half of theMyt1+ cells (n=6) in theMyt1btet2; Pdx1tTA/tTA pancreas turned
on glucagon expression (Figs. 2B–E). By E18.5, only rare glucagon+ cells
could be detected in Myt1btet2; Pdx1tTA/tTA pancreata. This ﬁnding
suggests that without Pdx1-dependent cell expansion or survival
(Jonsson et al., 1994; Ofﬁeld et al., 1996), early glucagon+ cells might
have died or have trans-differentiated into other cell types, possibly due
to the lack of paracrine signals produced by Pdx1+ cells or other
unknown reasons.
Because only one Myt1btet transgenic mouse line could produce
ectopic Myt1b protein in pancreatic progenitors, we veriﬁed our above
ﬁndings by generating other transgenic mouse lines that ectopically
expressedMyt1b.We derived Pdx1–Myt1btgmice, in whichMyt1bwas
ectopically expressed under the control of a 4.3 kb Pdx1 promoter. This
promoter fragment is known to drive transgene expression in a pattern
similar to that of endogenous Pdx1 (Wu et al., 1997). Three Pdx1–
Myt1btg embryos that expressed ectopicMyt1bwere obtained. In these
pancreata, a 2.3 fold increase in glucagon+ cells was observed. Similar
toMyt1btet2; Pdx1tTA/tTA pancreata, many Myt1b+ cells in Pdx1–Myt1btg
pancreata failed to activate glucagon expression (Supplementary Fig.
2). These ﬁndings demonstrate that Myt1b promotes endocrine
differentiation, yet Myt1b has a weaker endocrine inducing capability
than Ngn3.
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cells in Myt1btet2; Pdx1tTA/+ and Myt1btet2; Pdx1tTA/tTA animals, we ex-
amined whether endocrine differentiation could be induced byMyt1b
ectopic expression in these non-pancreatic cells at E10.5 and E12.5.
The number of hormone (glucagon, insulin, SS and PP) expressing
cells remained identical in the duodenal and stomach tissues in
animals that did or did not ectopically express Myt1b (data not
shown). These data demonstrate that ectopic Myt1b production
cannot convert speciﬁed duodenal and stomach cells into endocrine
islet cells.
Ectopic Myt1b-induced glucagon-expressing cells are immature α cells
Endocrine islet cell production in the mouse embryonic pancreas
occurs in two phases. From E9–E12.5, mostly glucagon expressing α
cells are produced (Jensen et al., 2000a). The production of these cells
does not require Pdx1 activity and these cells might not contribute
signiﬁcantly to adult islet pool (Herrera, 2000; Ofﬁeld et al., 1996).
These early glucagon-expressing cells are therefore considered
immature endocrine cells and are shown to express the protein
convertase, PC1/3 (Wilson et al., 2002). After E12.5, all four endocrine
cell types are produced and the mature α cells switch off PC1/3
expression.
We determined whether the Myt1b-induced endocrine cells were
mature α cells by analyzing their expression of PC1/3 and other known
α cell markers, including MafB (Artner et al., 2007) and Nkx6.1
(Henseleit et al., 2005). Most, if not all, glucagon expressing cells in the
Myt1btet2; Pdx1tTA/+ or the Myt1btet2; Pdx1tTA/tTA pancreata (E12.5)
produced high levels of PC1/3 (Supplementary Fig. 3A and Fig. 3A),
suggesting that induced glucagon-expressing cells, regardless of the
presence or absence of Pdx1, are immature α cells. In addition, MafB
expression was observed in nearly all glucagon+ cells in theMyt1btet2;
Pdx1tTA/+ or Myt1btet2; Pdx1tTA/tTA pancreas as in control littermates
(Supplementary Fig. 3B and Fig. 3B), suggesting thatMyt1b is sufﬁcient
to activate MafB expression. Interestingly, ectopic Myt1 expression
signiﬁcantly increased the number of Nkx6.1+ pancreatic cells: at
E12.5, there was a 273±160% increase of Nkx6.1+ cells in theMyt1btet2;
Pdx1tTA/tTA pancreata over that of the Pdx1tTA/tTA littermates (Figs. 3C
andD). Because Nkx6.1/Nkx6.2were reported to be required for strong
Myt1b expression and α cell differentiation, this latter ﬁnding
demonstrates a possible feedback activation link between Myt1 andFig. 3. Myt1b ectopic expression induces the expression of α cell markers. Sections of E12.5 p
PC1/3 in Myt1b induced endocrine cells. (B and C)MafB and Nkx6.1 expression in pancreata th
channels and one merge. tTA/tTA=Pdx1tTA/tTA. 1b;tTA/tTA=Myt1btet2; Pdx1tTA/tTA. White arroNkx6.1/Nkx6.2 transcription factors (Henseleit et al., 2005). This result
is also consistentwith the ﬁnding thatNkx6.1 expression ismaintained
in the glucagon expressing cells of Pdx1−/− mutant pancreas (Pedersen
et al., 2005).
Myt1b induces endocrine differentiation through Ngn3
Wenext examined howMyt1 induces endocrine differentiation. Our
published results suggest thatMyt1b partially represses Notch signaling
in endodermal cells, an essential process for Ngn3 expression activation
(Ahnfelt-Ronne et al., 2007a; Xu et al., 2006). We therefore examined
whether Myt1b ectopic expression activates Ngn3 expression. Embryos
that ectopically expressedMyt1bwere obtained at different stages, and
pancreatic Ngn3-expressing cells were counted. At E10.25, the number
of Ngn3+ cells in Myt1btet2; Pdx1tTA/+ pancreata increased by 136±22%
over that of Pdx1tTA/+ littermates (Fig. 4A and Supplementary Fig. 4),
consistent with the ﬁndings that more glucagon-expressing cells were
produced in pancreata with ectopic Myt1b expression. Enhanced Ngn3
expression was observed in Myt1btet2; Pdx1tTA/tTA pancreas as well. At
E9.5 and E10.25,Myt1btet2; Pdx1tTA/tTA pancreata contained visibly more
Ngn3+ cells than wild type littermates (Figs. 4B and 4C). Notably,
glucagon+Ngn3+ cells were detected in Myt1btet2; Pdx1tTA/tTA pancreata,
but not in control littermates (Fig. 4C). At E10.25, Pdx1tTA/tTA pancreas
producednomore than twoNgn3+ cells (n=10), yetMyt1btet2; Pdx1tTA/tTA
embryos produced an average of 12 Ngn3+ cells per pancreas (n=10).
These data suggest thatMyt1b can induceNgn3 expression andpromote
endocrine differentiation, even in the absence of Pdx1.
Because Myt1 is expressed in both endocrine progenitor cells and
differentiated adult islet cells (Wang et al., 2007), it is possible that
Myt1 acts as a downstream target of Ngn3 to mediate endocrine dif-
ferentiation. In this case,Myt1 should induce endocrine differentiation
in the absence of Ngn3. To investigate this possibility, we derived a
targeted conditional Ngn3 allele, which has the Ngn3 coding region
ﬂanked by two LoxP sites to potentially produce aNgn3null allele (Figs.
4D–F). Myt1btet2; Pdx1tTA/tTA; Ngn3−/− embryos were obtained, such
thatMyt1bwas ectopically expressed inNgn3 nullizygous background.
Eliminating Ngn3 activity nearly abolished glucagon expression with
Myt1b ectopic expression (Fig. 4G). These data provide strong genetic
evidence that Ngn3 is required for Myt1b-induced endocrine differ-
entiation, i.e. Myt1b induces endocrine differentiation through
activation of Ngn3.ancreata. Pdx1tTA/tTA pancreata were used as controls. (A) Co-expression of glucagon and
at ectopically expressMyt1b, respectively. Each sample contains two single ﬂuorescence
ws in panel B point to blood cells. All panels used identical scales, bar=20 μm.
Fig. 4. Myt1b induces glucagon expression through Ngn3. Hemizygous pancreata containing Pdx1tTA and other mutations were utilized (tTA=Pdx1tTA. Myt1b=Myt1btet2). (A) The
relative number of Ngn3+ cells in Myt1b; Pdx1tTA/+ pancreata over that of wild type control littermates at E10.25 (n=7, P=0.015). (B) The average number of Ngn3+ cells in Pdx1−/−
pancreata that ectopically express Myt1b at E10.25. (C) Immunoﬂuorescence showing Ngn3 production in pancreata that ectopically expressMyt1b. Two stages, E9.5 and E10.25, are
shown. Note the presence of glucagon+Ngn3+ cells (white arrows) in pancreata with ectopic Myt1 expression. Red, Ngn3. Green, glucagon. (D–F) The production and genotyping
strategies of a novel Ngn3 null allele (Ngn3−). (D) The structure of the Ngn3wild type, ﬂoxed (Ngn3F) and null allele. A PmeI site was introduced in the 5′end of the Ngn3 coding cDNA
in the Ngn3F allele. Also note that the Ngn3− allele produces CreER™ a feature that is not used in this study. (E) Southern blot identiﬁes four targeted ES cell clones, producing a
8.1 kb wild type and a 6.4 kb mutant bandwhen digested with XbaI+PmeI and blotted with P1 probe. The numbers (45, 722, and 723) and small arrows indicate the position of oligos
used for PCR-based genotyping (F). (G) Myt1b-induced glucagon expression in pancreata with or without Ngn3 at E12.5. Note the rare glucagon+ cells (green, white arrowhead) in
Ngn3−/− mutant pancreas. Red, Myt1. All panels utilized identical scales, bar=20 μm.
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We next examined whether endogenous Myt1 expression totally
depends on Ngn3. E10.5, E12.5, E13.5, and E15.5 Ngn3 nullizygous
pancreata were obtained. Pancreatic Myt1+ cells were detected in all
stages examined (Fig. 5). The pancreatic identity of these Myt1+ cells
was conﬁrmed by the surprising ﬁndings that a portion of theseMyt1+
cells co-expressed glucagon (Figs. 5A–C) and MafB (Fig. 5D). AfterFig. 5. Ngn3−/− mutant pancreas maintains Myt1 and glucagon expression. Glucagon (green
pancreata. (E–H) Wild type pancreata. White arrowheads point to glucagon+Myt1+ cells inE15.5, no glucagon+ cells could be found in Ngn3−/− pancreas, although
Pdx1+Myt1+ cells could still be detected (Supplementary Fig. 5). At all
stages examined, the number of Myt1+ cells represented less than 5%
of that of the wild type littermate, demonstrating that Myt1
expression is largely, but not totally, dependent on Ngn3. At present,
we do not know whether these Myt1+ cells depend on the activation
of Ngn3 paralogs, Ngn1 and Ngn2 (Sommer et al., 1996), in the Ngn3
null background.), Myt1 or MafB (red) expression at three stages, E9.5, E12.5, and E13.5. (A–D) Ngn3−/−
Ngn3−/− pancreata. All panels used identical scales, bars=10 μm.
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The dramatic reduction of Myt1 expression in Ngn3−/− pancreata
suggests that Ngn3 activatesMyt1 expression. Indeed, in the Ngn3tet8;
Pdx1tTA/+ pancreata, where Ngn3 was ectopically expressed in most, if
not all, of the Pdx1+ progenitors at early embryonic stages, Myt1
production was dramatically increased (Figs. 6A and B).
We further analyzed whether Ngn3 can activate the Myt1b pro-
moter in tissue culture. Alignment of mouse, rat, human and chicken
genomic DNA sequences upstream of the respective Myt1b transcrip-
tion initiation site revealed several DNA blocks that are highly con-
served in all four species (Fig. 6C), suggesting that these DNA elements
constitute the promoter that regulates the pancreatic and/or neuronal
Myt1 expression. The putative mouseMyt1b promoter was utilized to
drive a luciferase reporter gene in 3T3ﬁbroblast andP19 carcinoma cell
lines. Ngn3 activated the Myt1b promoter in both cell lines (Figs. 6D
and E). Amutant Ngn3 protein, which contained a N89Dmutation that
inactivated its DNA binding activity, could not activate the Myt1b-
luciferase reporter (Fig. 6D).
Myt1 is likely a transcriptional activator during endocrine differentiation
A dominant negative Myt1b molecule represses endocrine differ-
entiation in both mouse and chicken tissues (Ahnfelt-Ronne et al.,
2007b; Gu et al., 2004). Loss of the endogenousMyt1 function partially
impairs endocrine differentiation and adult islet function (Wang et al.,
2007). However, it is not clear whether Myt1b behaves as a trans-Fig. 6. Ectopic Ngn3 expression induces Myt1 expression. (A and B) Myt1 and Ngn3
expression in pancreata that ectopically express Ngn3. (C) Genomic pair-wise alignment
of Myt1 promoters from different species. Grey peaks indicate conserved regions. The
pink column indicates the ﬁrst exon. The 1.8 kb Myt1b promoter region used for
reporter assays is marked by a light green bar on top. (D and E) Myt1 promoter activity
assays in 3T3 and P19 cell lines. In each cell line, mock transfected, Ngn3, and a mutant
Ngn3 (N89D) expressing vectors were co-transfected with the respective luciferase
reporter plasmid. * denotes that the differences between control and experimental
groups were statistically signiﬁcant. Scale bars=10 μm.criptional repressor or activator in the endocrine differentiation pro-
cess. To test these possibilities, we created artiﬁcial reading frames that
encoded a Myt1-activator and a Myt1-repressor protein, respectively.
The Myt1-activator was a fusion between the second and third zinc
ﬁngers of Myt1b and the VP16 trans-activation domain and the Myt1-
repressor was a fusion between the same zinc ﬁngers and the EnR
repressor domain (Fig. 7A). We expected that these proteins would
possess activator or repressor activities thatwere inherent to VP16 and
EnR, respectively (Bellefroid et al.,1996), yet would bind the sameDNA
elements recognized by Myt1b. If Myt1b behaves as a transcriptional
activator during endocrine differentiation, we expect that the Myt1–
VP16 protein to substituteMyt1 for inducing endocrine differentiation,
whereas Myt1–EnR would repress endocrine differentiation. Vice
Versa, if Myt1 behaves as a transcriptional repressor during endocrine
differentiation, we expect that the Myt1–EnR protein to substitute
Myt1 for inducing endocrine differentiation, whereas Myt1–VP16 to
inhibit islet cell production.
Chicken embryos were electroporatedwithNgn3 expressing vector
alone or in combinationwith plasmids that expressed either of the two
above fusion proteins. As previously reported (Grapin-Botton et al.,
2001), Ngn3 ectopic expression in chicken embryonic endodermal
cells caused epithelial cells to delaminate from the gut tube and turned
on the expression of endocrine markers such as glucagon and Pax6
(Grapin-Botton et al., 2001).WhenNgn3was expressed in combination
with Myt1–VP16, both glucagon and Pax6 could be detected in the
electroporated cells, suggesting that activation of Myt1 target genes
(by Myt1–VP16) has minimal effect on Ngn3-induced endocrine
differentiation (Figs. 7B–D). In contrast, the presence of Myt1–EnR
substantially reduced the differentiation induced by Ngn3 ectopic
expression (Figs. 7E–G). Although Ngn3 and Myt–EnR vectors electro-
porated cells still delaminated from the endodermal epithelium, the
number of glucagon positive cells was reduced and the electroporated
cells appeared more scattered (compare Figs. 7F and 7C). Signiﬁcantly,
Myt1–EnR almost completely blocked the expression of Pax6 induced
by Ngn3 (compare Figs. 7G and D). These data demonstrate that
convertingMyt1b into a transcription repressor inhibits Ngn3-induced
endocrine differentiation, i.e. Myt1b acts as a transcriptional activator
for endocrine differentiation. Interestingly, Myt1–EnR did not prevent
the epithelial cell from delaminating, suggesting that endocrine
hormone expression and epithelial delamination are mediated by
distinct pathways initiated by Ngn3 (Figs. 7B, C, E, and F).
Discussion
Loss or attenuation of endocrine function, particularly that of the
insulin-producing β cells, results in diabetes mellitus. Because reple-
nishing lost β cells provides a potential cure for diabetes, under-
standing how endocrine islet cells develop in vivo and whether such
mechanisms could be explored for ES cell-based cell production in
vitro or for inducing β cell regeneration in vivo has attracted much
attention in the past decade (Blyszczuk and Wobus, 2006; Bonner-
Weir andWeir, 2005; Colman, 2004; Heit and Kim, 2004; Kaczorowski
et al., 2002; Kania et al., 2004; Noguchi, 2007; Santana et al., 2006;
Schroeder et al., 2006). To this end, identifying molecules capable of
inducing endocrine cell differentiation in animal models and elucidat-
ing their mechanism of action are particularly valuable for diabetes
research.
Here, we show thatMyt1 andNgn3 form a feed-forward expression
loop to promote the differentiation of most, if not all endocrine cells.
This ﬁnding is consistent with a simpliﬁed model where Myt1 activ-
ation provides an exit mechanism to break the Ngn3 self-inhibitory
loop. This allows the development of high levels of Ngn3 expression
required for endocrine commitment (Fig. 8). In particular, it is likely
that during endocrine differentiation, a slight ﬂuctuation in Notch
activity, caused by stochastic gene expression (Kaern et al., 2005) and/
ormodiﬁcation by the Fringemolecules (Xu et al., 2006), initiatesMyt1
Fig. 7. Transactivating properties of Myt1 is required for endocrine differentiation. (A) A scheme showing the structures of Myt1–EnR and Myt1–Vp16. cDNA encoding zinc ﬁngers 2
and 3 of Myt1b was cloned in framewith the engrailed repressive domain (Myt1–EnR) or the VP16 activation domain (Myt1–VP16) to obtain the desired open reading frames. (B–G)
Endocrine marker expression in chicken endodermal cells electroporated with different DNA constructs, all shown as confocal image projections. (B) A chicken embryo
electroporated with EGFP alone. Note that electroporated cells (green) could be observed in the dorsal part of the gut tube while glucagon-expressing cells (red) could only be
detected in the dorsal pancreas. (C and D) Results of Ngn3 and Myt1–VP16 co-expression. Note the expression of glucagon (C) and Pax6 (D) in electroporated cells (green). The
endogenous pancreas in panel C is outside of the view. (E) An embryo electroporated with mouse Ngn3 expressing plasmid alone. Note glucagon expression outside the pancreatic
bud (white broken lines). (F and G) Embryos with Ngn3 and Myt1–EnR co-expression. Note the delamination of electroporated cells with or without Myt1–EnR production outside
the endogenous pancreas (white broken lines, F). Also note the dramatic reduction in the number of Pax6+ cells in the cells that ectopically express Ngn3 andMyt1–EnR (G). In panels
B, C, E, and F, Foxa2 expression (grey color) highlights the gut tube. Bars=20 μm.
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lecules then ensures robust Ngn3 production so that the cell could
escape lateral inhibition and differentiate. This model is consistent
with several other ﬁndings: (1) In Xenopus, xMyT1 and xNgnR1 (Myt1
and Ngn3 orthologues) co-expression allows for neuronal differentia-
tion independent of Notch activation, whereas each molecule alone is
unable to do so (Bellefroid et al., 1996); (2) In chicken embryonic en-
dodermal cells, Ngn3-induced endocrine differentiation (Grapin-
Botton et al., 2001) could be repressed by a constitutively active
Notch molecule, NICD, suggesting that Ngn3 is not the only Notch
target required for endocrine differentiation (Ahnfelt-Ronne et al.,Fig. 8. A model for Myt1–Ngn3 interaction. Notch inactivation may induce the
expression of Myt1 and Ngn3. The presence of bothMyt1 and Ngn3 promotes endocrine
differentiation synergistically.2007a); (3) As presented in this manuscript, Ngn3-independent Myt1
expression is detected in pancreatic cells. Taken together, these studies
suggest that the feed-forward expression between Myt1 and Ngn3
plays a critical role in proper endocrine differentiation. Nonetheless,
because the time frame for Ngn3 expression within a particular cell is
not clear, nor how long it takes for Ngn3 to induceMyt1 expression, our
data do not directly prove the abovemodel. It is likely that a combined
loss ofMyt1/Myt1L/Myt3will be required to directly examinewhether
this family of proteins is required to potentiateNgn3 expression during
endocrine speciﬁcation.
Ectopic Myt1b expression in early pancreatic progenitors, like
Ngn3, only results in the production of glucagon expressing cells, the
cell type produced during the ﬁrst wave endocrine differentiation
(Apelqvist et al., 1999; Grapin-Botton et al., 2001; Schwitzgebel et al.,
2000). These data suggest that Myt1b, like Ngn3, does not direct islet
cell type speciﬁcation when precociously expressed in early endo-
crine progenitors. Instead, the ﬁnal identity of the endocrine cell type
is likely determined by the nature, or cellular competence, of the
pancreatic progenitor cells, as demonstrated recently by temporally
controlled Ngn3 activation in pancreatic progenitor cells (Johansson
et al., 2007). Nonetheless, because we were unable to speciﬁcally
activate Myt1b expression in Myt1btet2; Pdx1tTA/+ or Myt1btet2;
Pdx1tTA/tTA pancreas at later embryonic stages using Dox, we could
not test this hypothesis directly. It is puzzling thatwe could not achieve
signiﬁcant ectopic gene activation in later embryonic stages and in
postnatal pancreas with any of the Tet-based Myt1b and Ngn3 (data
not shown) transgenic mouse lines. One possibility is that due to the
lethality caused by the leakiness of the Tet-Myt1b and tet-Ngn3
transgenes, only weak responder mice can survive to produce stable
mouse lines. In this case, later pancreatic progenitorsmayhave a lower
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epigenetic modiﬁcation of the transgene or other unknown mechan-
ism(s) can repress the transgene expression at later embryonic stages.
While Ngn3 ectopic expression in pancreatic progenitors directs
most, if not all of the pancreatic progenitors to an endocrine fate, only a
portion of the ectopicMyt1+ cells switches onhormone expression. It is
possible that Myt1 only accelerates the differentiation of progenitor
cells that have a low level of Ngn3 expression towards endocrine fate.
These low-Ngn3-expressing cells, without the presence of Myt1b
expression, may not become high Ngn3 expressors and thus may not
undergo endocrine differentiation. It would be interesting to examine
whether loss of Myt1 function compromise Ngn3 expression in
developing pancreatic cells. Due to compensatory activation of Myt1L
and Myt3 in Myt1−/− pancreas, resolving this issue will likely require
the simultaneous inactivation of Myt1, Myt1L and Myt3 in the future.
One surprising ﬁnding is that a small, yet signiﬁcant, number of
glucagon+ cells was observed in the Ngn3−/− pancreata before E15.5,
after which these cells disappeared. Most of these cells expressed
Myt1. One explanation for this observation is that these rare endocrine
cells were produced in a Ngn-independent manner, where Myt1 itself
is sufﬁcient to switch on the endocrine differentiation. Alternatively, it
is possible that the hormone expressing cells in the Ngn3−/− pancreas
are the result of compensatory expression of Ngn1 and/or Ngn2, with
which Myt1b could cooperate to induce endocrine differentiation
(Sommer et al., 1996). In addition, we do not know why endocrine
hormone expressing cells could not be detected in Ngn3−/− pancreas in
other settings, as reported by others (Gradwohl et al., 2000). One
possibility is that a slight variation in the genetic background makes
some animals more liable for compensatory expression of Ngn3 para-
logs. This possibility could be explored by breeding the null Ngn3
mutation to pure genetic backgrounds in the future. Nonetheless, the
detection of these endocrine cells in Ngn3−/− pancreas bolsters the
notion that endocrine progenitors are heterogeneous in terms of their
origin. In practice, it suggests that functional islet cells could be ob-
tained from Ngn3-independent pathways under speciﬁc growth
conditions.
Overall, this study suggests that Myt1 and Ngn3 form a feed-
forward loop to enhance the expression of each other (Fig. 8). This
synergistic effect could act to ensure that a sufﬁcient number of
endocrine islet cells are produced during embryogenesis. It further
emphasizes the importance of introducing gene networks rather than
single gene products to cells in order to obtain differentiated cells for
regenerative medicine.
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